Abstract: The present invention relates to compounds of Formula (I): wherein R1 to R3 are as described herein, processes for preparing the compounds, pharmaceutical compositions comprising the compounds, and use of the compounds and compositions in the prophylaxis or treatment of a GHSR receptor-related disorder. Examples of such disorders are obesity and related disorders such as diabetes type II, dyslipidemia and the metabolic syndrome Prader-Willi syndrome, cardiovascular diseases such as atherosclerotic vascular disease, angina pectoris, myocardial infarction and stroke, intestinal inflammation that is associated with inflammatory bowel diseases (IBD) such as Crohn's disease and ulcerative colitis, acromegaly and cancer, in particular breast, lung, prostate, thyroid and endocrine pituary carcinomas.

Abstract: The invention provides novel compounds or the formula II: wherein R1, R2, R3 and R4 are independently hydrogen of a group that liberates the free amine in vivo, for example —CO-alkyl, preferably —CO—C1-C3 alkyl or pivalate; or —COhaloalkyl, preferably —CO—C1-C3 haloalkyl, most preferably —CO—C1-C3 chloroalkyl; wherein W is: and @ denotes the points of attachment and wherein the ester can be located in either direction; wherein n and m are independently 0-5; wherein one but not both or X and Y can be nitrogen, or X is C-A and/or Y is C—B; wherein A and B are independently selected from hydrogen, alkyl optionally substituted with a halogen, an electron donor group such as amino, alkylamino, dialkylamino or hydroxy, or an electron acceptor group such as nitro, cyano. trihaloalkyl or amido, alkoxy or halogen; and pharmacologically acceptable salts thereof.

Abstract: Compounds of the formula I: 1